The listing of the claims will replace all prior versions, and listings, of the claims in the application.

## LISTING OF THE CLAIMS

1. (*previously presented*) A method for treating hot flushes, excessive perspiration or night sweats in a subject in need thereof, comprising the step of:

administering to said subject a composition, comprising:

a therapeutically effective amount of at least one norepinephrine reuptake inhibitor or pharmaceutically acceptable salt thereof, wherein the norepinephrine reuptake inhibitor is not a dual serotonin reuptake inhibitor / norepinephrine reuptake inhibitor;

wherein said norepinephrine reuptake inhibitor is selected from the group consisting of: maprotiline; desipramine; nisoxetine; atomoxetine; amoxapine; 1-[1-(3-fluorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol; 1-[1-(3-chlorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol; 1-[2-(4-methyl-1-piperazinyl)-1-[3-(trifluoromethyl)-phenyl] ethyl]cyclohexanol; 1-[1-(4-methoxy phenyl)-2-[4-methyl-1-piperazinyl)ethyl]cyclohexanol; 1-[1-(3-chlorophenyl)-2-[4-(3-chlorophenyl)-1-piperazinyl]ethyl]cyclohexanol; 1-[1-(3-methoxyphenyl)-2-[4-phenylmethyl)-1-piperazinyl]ethyl]cyclohexanol; 1-[2-(3-chloro phenyl)-1-piperazinyl]-1-[3-methoxyphenyl)ethyl]cyclohexanol; 1-[2-[4-(6-chloro-2-pyrazinyl)1-piperazinyl]-1-[3-methoxyphenyl)ethyl]cyclohexanol; 1-[2-[4-(phenylmethy1)l- 1 -piperazinyl]-1-[3-(trifluoromethyl)phenyl] ethyl]cyclohexanol; 1-[1-(3-methoxyphenyl)-2-[4-[3-(trifluorometh1)-phenyl]-1-piperazinyl]ethyl]cyclohexanol; 1-[1-(4-fluorophenyl)-2-[4-(phenylmethy1)-1-piperazinyl] ethyl]cyclohexanol; 1-[1-(3-methoxyphenyl)-2-[4-[3-(trifluoromethyl)-phenyl-1-piperazinyl]ethyl]cyclopentanol; 1 -[1-(4-fluorophenyl)-2-[4-(phenylmethy1)-1-piperazinyl] ethyl]cyclohexanol; 1 -[2-(dimethylamino)- 1 -(3 -trifluoromethyl phenyl)ethyl]cyclohexanol; 1-[1-(3-fluorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol; 1-[1-(3-chlorophenyl)-2-(dimethylamino)ethyl cyclohexanol; 1-[2-dimethylamino)-1-(3-trifluoromethylphenyl)ethyl]cyclohexanol; 1-[1-(3-chlorophenyl)-2-piperazin-1-yl-ethyl]-cyclohexanol; and combinations and pharmaceutically acceptable salts thereof.

2-6. *(canceled)*

7. *(previously presented)* A method according to claim 1, wherein said norepinephrine reuptake inhibitor is desipramine or pharmaceutically acceptable salt thereof.

8. *(withdrawn-previously presented)* A method according to claim 1, wherein said norepinephrine reuptake inhibitor is 1-[1-(3-chlorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol or pharmaceutically acceptable salt thereof.

9. *(withdrawn-previously presented)* A method according to claim 8, wherein said norepinephrine reuptake inhibitor is a pure enantiomer of 1-[1-(3 -chlorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol.

10. *(original)* A method according to claim 1, wherein said composition further comprises a therapeutically effective amount of at least one serotonin reuptake inhibitor or a pharmaceutically acceptable salt thereof.

11. *(original)* A method according to claim 10, wherein said serotonin reuptake inhibitor is selected from the group consisting of fluoxetine, paroxetine, sertraline, fluvoxamine, and combinations and pharmaceutically acceptable salts thereof.

12. *(previously presented)* A method according to claim 10, wherein said norepinephrine reuptake inhibitor and said serotonin reuptake inhibitor are administered concurrently.

13. *(original)* A method according to claim 1, wherein said composition further comprises a therapeutically effective amount of at least one adrenergic$_{\alpha2}$ receptor antagonist or a pharmaceutically acceptable salt thereof.

14. *(previously presented)* A method according to claim 13, wherein said norepinephrine reuptake inhibitor and said adrenergic$_{\alpha2}$ receptor antagonist are administered concurrently.

15. *(previously presented)* A method according to claim 13, wherein said norepinephrine reuptake inhibitor and said adrenergic$_{\alpha2}$ receptor antagonist are administered simultaneously.

16. *(canceled)*

17. *(original)* A method according to claim 13, wherein said adrenergic$_{\alpha2}$ receptor antagonist is a compound selected from the group consisting of atipamezole; 2-[2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl]-4,4-dimethyl-1,3-(2H,4H)-isoquinolindione dihydrochloride (ARC 239 dihydrochloride); 2-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2,3-

dihydro1-methyl-1H-isoindole maleate (BRL 44408 maleate); BRL48962; BRL41992; SKF 104856; SKF 104078; MK912; 2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-4,5-dihydro-1H-imidazole hydrochloride (efaroxan hydrochloride); 2-(1,4-benzodioxan-2-yl)-2-imidazoline hydrochloride (idazoxan hydrochloride); 2-(1-ethyl-2-indazoyl)methyl-1,4-benzodioxan hydrochloride (imiloxan hydrochloride); 17α-hydroxy-20α-yohimban-16β-carboxylic acid, methyl ester hydrochloride (rauwolscine hydrochloride); (8αR,12αS, 13αS)-5,8,8α,9,10,11,12,12α,13,13α-dechydro-3-methoxy-12-(ethylsulfonyl)-6H-isoquino[2,1-γ][1,6]naphthyridine hydrochloride (RS 79948 hydrochloride); 2-(2,3-dihydro-2-methoxy-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole hydrochloride (RX 821002 hydrochloride); 8-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one (spiroxatrine); 17α-hydroxyyohimban-16α-carboxylic acid methyl ester hydrochloride (yohimbine hydrochloride); and combinations and pharmaceutically acceptable salts thereof.

18. *(original)* A method according to claim 13, wherein said adrenergic$_{\alpha2}$ receptor antagonist is selective for the adrenergic$_{\alpha2A}$ receptor.

19. *(original)* A method according to claim 13, wherein said adrenergic$_{\alpha2}$ receptor antagonist is selective for the adrenergic$_{\alpha2B}$ receptor.

20. *(original)* A method according to claim 13, wherein said adrenergic$_{\alpha2}$ receptor antagonist is selective for the adrenergic$_{\alpha2C}$ receptor.

21. *(original)* A method according to claim 13, wherein said adrenergic$_{\alpha2}$ receptor antagonist is selective for the adrenergic$_{\alpha2D}$ receptor.

22. *(original)* A method according to claim 1, wherein said pharmaceutically acceptable salt is an acid addition salt.

23. *(canceled)*

24. *(original)* A method according to claim 1, wherein said subject is human.

25. *(original)* A method according to claim 24, wherein said human is a female.

26. *(original)* A method according to claim 25, wherein said female is pre-menopausal.

27. *(original)* A method according to claim 25, wherein said female is peri-menopausal.

28. *(original)* A method according to claim 25, wherein said female is post-menopausal.

29. *(original)* A method according to claim 24, wherein said human is a male.

30. *(original)* A method according to claim 29, wherein said male is naturally, chemically or surgically andropausal.

31. *(withdrawn-previously presented)* A pharmaceutical composition, comprising:

a. at least one norepinephrine reuptake inhibitor selected from the group consisting of maprotiline; reboxetine; norpramine, nisoxetine; atomoxetine; amoxapine; doxepin; lofepramin; amitryptyline; 1-[1-(3 -fluorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol; 1-[l-(3-chlorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexano1; 1-[2-(4-methyl-1-piperazinyl)-1-[3-(trifluoromethy1)-phenyllethyl]cyclohexanol; 1-[1-(4-methoxy phenyl)-2-[4-methyl-1 -piperazinyl)ethyl]cyclohexanol; 1-[1-(3 -chlorophenyl)-2-[4-(3-chlorophenyl)-1-piperazinyl]ethyl]cyclohexanol; 1-[1-(3-methoxyphenyl)-2-[4-phenyl methyl)-1-piperazinyl]ethyl]cyclohexanol; 1-[2-(3-chloro phenyl) 1-piperazinyl-1-[3-methoxyphenyl)ethyl]cyclohexanol; 1-[2-[4-(6-chloro-2-pyrazinyl)-1-piperazinyl]-1-[3-methoxyphenyl)ethyl]cyclohexanol; 1-[2-[4-(phenyl methyl)]-1-piperazinyl]-1-[3-(trifluoromethyl)phenyl]ethyl]cyclohexanol; 1-[1-(3-methoxyphenyl)-2-[4-[3-(trifluoro methyl)-phenyll-1-piperazinyl]ethyl]cyclohexanol; 1-[l-(4-fluorophenyl)-2-[4-(phenylmethy1)-1-piperazinyl]ethyl]cyclohexanol; 1-[1-(3-methoxyphenyl)-2-[4-[3-(trifluoromethyl)-phenyl]-1-piperazinyl]ethyl]cyclopentanol; 1-[1-(4-fluorophenyl)-2-[4-(phenylmethy1)-1-piperazinyl]ethy1]cyclohexanol; 1-[2-(dimethylamino)-1-(3-trifluoromethyl phenyl)ethyl]cyclohexanol; 1-[1-(3-fluorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol; 1-[1-(3-chlorophenyl)-2-(dimethylamino)ethyl]cyclohexanol; 1-[2-dimethylamino)-1-(3-trifluoromethylphenyl)ethyl]cyclohexanol; 1-[1-(3-chlorophenyl)-2-piperazin-1-yl-ethyl]-cyclohexanol; and combinations and pharmaceutically acceptable salts thereof;

b. at least one serotonin reuptake inhibitor or a pharmaceutically acceptable salt thereof; and

c. at least one pharmaceutically acceptable carrier.

32. *(withdrawn)* A pharmaceutical composition according to claim 31,

wherein said pharmaceutically acceptable salt is an acid addition salt.

33 - 34. *(canceled)*

35. *(withdrawn)* A pharmaceutical composition according to claim 31, wherein said norepinephrine reuptake inhibitor is 1-[1-(3-chlorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol.

36. *(withdrawn)* A pharmaceutical composition according to claim 35, wherein said norepinephrine reuptake inhibitor is a pure enantiomer of 1-[1-(3-chlorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol.

37. *(withdrawn)* A pharmaceutical composition according to claim 31, wherein said serotonin reuptake inhibitor is selected from the group consisting of fluoxetine, paroxetine, sertraline, fluvoxamine, and combinations and pharmaceutically acceptable salts thereof.

38. *(withdrawn-previously presented)* A pharmaceutical composition, comprising:

a. at least one norepinephrine reuptake inhibitor selected from the group consisting of maprotiline; reboxetine; norpramine, nisoxetine; atomoxetine; amoxapine; doxepin; lofepramin; amitryptyline; 1-[1-(3 -fluorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol; 1-[1-(3-chlorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexano1; 1-[2-(4-methyl-1-piperazinyl)-1-[3-(trifluoromethy1)-phenyllethyl]cyclohexanol; 1-[1-(4-methoxy phenyl)-2-[4-methyl-1-piperazinyl)ethyl]cyclohexanol; 1 - [ 1 -(3 -chlorophenyl)-2-[4-(3-chlorophenyl)-1-piperazinyl]ethyl]cyclohexanol; 1-[1-(3-methoxyphenyl)-2-[4-phenyl methyl)-1-piperazinyl]ethyl]cyclohexanol; 1-[2-(3-chloro phenyl) 1-piperazinyll-1-[3-methoxyphenyl)ethyl]cyclohexanol; 1-[2-[4-(6-chloro-2-pyrazinyl)-1-piperazinyl]-1-[3-methoxyphenyl)ethyl]cyclohexanol; 1-[2-[4-(phenyl methyl)]-1-piperazinyl]-1-[3-(trifluoromethyl)phenyl] ethyl]cyclohexanol; 1-[1-(3 -methoxyphenyl)-2-[4-[3-(trifluoro methyl)-phenyll-1-piperazinyl]ethyl]cyclohexanol; 1-[l-(4-fluorophenyl)-2-[4-(phenylmethy1)-1-piperazinyl] ethyl]cyclohexanol; 1-[1-(3-methoxyphenyl)-2-[4-[3-(trifluoromethyl)-phenyl] -1-piperazinyl] ethyl]cyclopentanol; 1-[1-(4-fluorophenyl)-2-[4-(phenylmethy1)-1 -piperazinyl]ethy1]cyclohexanol; 1-[2-(dimethylamino)-1-(3-trifluoromethyl phenyl)ethyl]cyclohexanol; 1-[1-(3-fluorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol; 1-[1-(3-chlorophenyl)-2-(dimethylamino)ethyl]cyclohexanol; 1-[2-dimethylamino)-1-(3-trifluoromethylphenyl)ethyl]cyclohexanol; 1-[1-(3-chlorophenyl)-2-piperazin-1-yl-ethyl]-cyclohexanol; and combinations and pharmaceutically acceptable salts thereof;

b. one adrenergic$_{\alpha 2}$ receptor antagonist selected from the group consisting of atipamezole; 2-[2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl]-4,4-dimethyl-1,3-(2H,4H)-isoquinolindione dihydrochloride (ARC 239 dihydrochloride); 2-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2,3-dihydro-1-methyl-1H-isoindole maleate (BRL 44408 maleate); BRL48962; BRL41992; SKF 104856; SKF104078; MK9 1 2; 2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-4,5-dihydro-1H-imidazole hydrochloride (efaroxan hydrochloride); 2-(1,4-benzodioxan-2-yl)-2-imidazoline hydrochloride (idazoxan hydrochloride); 2-(1-ethyl-2-indazoyl)methyl-1,4-benzodioxan hydrochloride (imiloxan hydrochloride); 17α-hydroxy-20α-yohimban-16β-carboxylic acid, methyl ester hydrochloride (rauwolscine hydrochloride); (8αR,12αS,13αS)-5,8,8α,9,10,11,12,12α,13,13α-dechydro-3-methoxy-12-(ethylsulfonyl)-6H-isoquino[2,1-γ][1,6]naphthyridine hydrochloride (RS 79948 hydrochloride); 2-(2,3-dihydro-2-methoxy-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole hydrochloride (RX 821002 hydrochloride); 8-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one (spiroxatrine); 17α-hydroxyyohimban-16α-carboxylic acid methyl ester hydrochloride (yohimbine hydrochloride); and combinations and pharmaceutically acceptable salts thereof; and

c. at least one pharmaceutically acceptable carrier.

39. *(withdrawn)* A pharmaceutical composition according to claim 38, wherein said pharmaceutically acceptable salt is an acid addition salt.

40. *(canceled)*

41. *(canceled)*

42. *(withdrawn)* A pharmaceutical composition according to claim 38, wherein said norepinephrine reuptake inhibitor is 1-[1-(3-chlorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol.

43. *(withdrawn)* A pharmaceutical composition according to claim 42, wherein said norepinephrine reuptake inhibitor is a pure enantiomer of 1-[1-(3-chlorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol.

44. *(canceled)*

45. *(withdrawn)* A pharmaceutical composition according to claim 38, wherein said adrenergic$_{\alpha 2}$ receptor antagonist is selective for the adrenergic$_{\alpha 2A}$ receptor.

46. *(withdrawn)* A pharmaceutical composition according to claim 38, wherein said adrenergic$_{\alpha 2}$ receptor antagonist is selective for the adrenergic$_{\alpha 2B}$ receptor.

47. *(withdrawn)* A pharmaceutical composition according to claim 38, wherein said adrenergic$_{\alpha 2}$ receptor antagonist is selective for the adrenergic$_{\alpha 2C}$ receptor.

48. *(withdrawn)* A pharmaceutical composition according to claim 38, wherein said adrenergic$_{\alpha 2}$ receptor antagonist is selective for the adrenergic$_{\alpha 2D}$ receptor.